診療ガイドラインに沿った　肝癌治療の要点と盲点

出版社： 文光堂
著者：
発行日： 2013-03-15
分野： 臨床医学：外科  >  消化器外科学
ISBN： 9784830618857
電子書籍版： 2013-03-15 （第1版第2刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

17,600 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

17,600 円(税込)

購入する

商品紹介

肝癌診療の現場では，「肝癌診療ガイドライン」が広く利用されているが，それだけでは解決できないケースにも遭遇する．例えば，治療アルゴリズムで推奨治療が複数記されている場合いずれを選ぶべきか？ 腫瘍数・径，肝障害度というアルゴリズムの決定因子以外の条件はどの程度考慮すべきか？ エビデンスが十分には確立していない治療は，どのように実践すべきか？ 本書は，そのような実臨床における様々な疑問に明快に答える一冊．

目次

  • 診療ガイドラインに沿った　肝癌治療の要点と盲点

    ―目次―

    I．肝癌治療選択のKnack & Pitfalls
    　1 ．肝癌診療ガイドラインの意義
    　2．肝癌診療ガイドラインの評価
    　3．肝癌治療アルゴリズムの解説
    　4．アルゴリズム構成因子の診断と評価
    　5．アルゴリズムに沿った治療方針 （Case study）
    　6．考慮すべき他の条件

    II．再発肝癌治療選択のKnack & Pitfalls
    　（1）単発再発
    　（2）多発再発
    　（3）局所再発
    　（4）血管侵襲
    　（5）肝外転移
    　（6）肝機能悪化

    III．肝癌治療実践のKnack & Pitfalls
    　1．肝切除
    　2．RFA
    　3．TACE
    　4．肝移植
    　5．化学療法
    　6．放射線治療

    IV．肝癌治療成績向上のKnack & Pitfalls
    　1 ．治療の質を支える病理
    　2．サーベイランスと発癌制御

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

P.6 掲載の参考文献
1) 科学的根拠に基づく肝癌診療ガイドライン作成に関する研究班編:科学的根拠に基づく肝癌診療ガイドライン,2005年版, 金原出版, 東京, 2005
 
2) 日本肝臓学会編:科学的根拠に基づく肝癌診療ガイドライン,2009年版, 金原出版, 東京, 2009
 
3) Kokudo N,et al:Dissemination of evidence-based clinical practice guidelines for hepatocellular carcinoma among Japanese hepatologists,liversurgeons and primary care physicians.Gut 56:1020-1021,2007
PubMed
4) 國土典宏,他:「科学的根拠に基づく肝癌診療ガイドライン」に関する日本肝癌研究会会員を対象としたアンケート調査報告.肝臓 48:562-570,2007
 
5) Song P,et al:The management of hepatocellularcarcinoma around the world:a comparison ofguidelines from 2001 to 2011.Liver Int 32:1053-1063,2012
 
P.10 掲載の参考文献
1) Arii S,et al:Results of surgical and nonsurgicaltreatment for small-sized hepatocellular carcinomas:a retrospective and nationwide survey in Japan.Hepatology 32:1224-1229,2000
 
2) Mazzaferro V,et al:Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med 334:693-699,1996
PubMed
3) Todo S,et al:Living donor liver transplantation for adult patients with hepatocellular carcinoma:experience in Japan.Ann Surg 240:451-459,2004
PubMed
4) Llovet JM,et al:Sorafenib in advanced hepatocellular carcinoma.N Engl J Med 359:378-390,2008
PubMed
5) Arii S,et al:Management of hepatocellular carcinoma:report of consensus meeting in the 45th annual meeting of the Japan Society of Hepatology(2009).Hepatol Res 40:667-685,2010
PubMed
P.13 掲載の参考文献
1) 日本肝移植研究会:肝移植症例登録報告.移植 46:524-536,2011
Medical*Online
2) 日本肝臓学会編:科学的根拠に基づく肝癌診療ガイドライン,2009年版, 金原出版, 東京, 2009
 
3) Shiratori Y,et al:Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.Ann Intern Med 132:517-524,2000
PubMed
4) Motosugi U,et al:Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease.J Magn Reson Imaging 34:88-94,2011
PubMed
5) Kumada T,et al:Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI.Am J Roentgenol 197:58-63,2011
 
P.15 掲載の参考文献
1) Bruix J,et al:Management of hepatocellular carcinoma.Hepatology 42:1208-1236,2005
PubMed
2) EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma.J Hepatol 56:908-943,2012
PubMed
3) Matsui O,et al:Hepatocelluar nodules in liver cirrhosis:hemodynamic evaluation(angiography-assisted CT)with special reference to multi-step hepatocarcinogenesis.Abdom Imaging 36:264-272,2011
PubMed
4) Nakashima O,et al:Pathomorphologic characteristics of small hepatocellular carcinoma:a special reference to small hepatocellular carcinoma with indistinct margins.Hepatology 22:101-105,1995
PubMed
5) Nakashima Y,et al:Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type.Hepatol Res 26:142-147,2003
PubMed
P.18 掲載の参考文献
1) 今井康陽,他:肝細胞癌の画像診断の進歩. 日消誌 108:916-927,2011
Medical*Online
2) Kogita S,et al:Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma:correlation with histological grading and portal blood flow.Eur Radiol 20:2405-2413,2010
PubMed
3) Sano K,et al:Imaging study of early hepatocellular carcinoma:usefulness of gadoxetic acid-enhanced MR imaging.Radiology 261:834-844, 2011
PubMed
4) Onishi H,et al:Hypervascular hepatocellular carcinomas:detection with gadoxetate disodium-enhanced MR imaging and multiphasic multidetector CT.Eur Radiol 22:845-854,2012
PubMed
5) Hyodo T,et al:Hypovascular nodules in chronic liver disease:Risk factors for developing hypervascular hepatocellular carcinoma.Radiology (inpress)
 
P.21 掲載の参考文献
1) Pathologic diagnosis of early hepatocellular carcinoma:a report of the international consensus group for hepatocellular neoplasia.Hepatology 49:658-664,2009
 
2) Nakashima O,et al:Pathomorphologic characteristics of small hepatocellular carcinoma:a special reference to small hepatocellular carcinoma with indistinct margins.Hepatology 22:101-105,1995
PubMed
3) Motosugi U,et al:Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease.J Magn Reson Imaging 34:88-94,2011
PubMed
4) Sugimoto K,et al:Comparison of Kupffer-phase Sonazoid-enhanced sonography and hepatobiliary-phase gadoxetic acid-enhanced magnetic resonance imaging of hepatocellular carcinoma and correlation with histologic grading.J Ultrasound Med 31:529-538,2012
PubMed
5) Kogita S,et al:Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma:correlation with histological grading and portal blood flow.Eur Radiol 20:2405-2413,2010
PubMed
P.23 掲載の参考文献
1) 日本肝癌研究会編:臨床・病理原発性肝癌取扱い規約,第5版補訂版, 金原出版, 東京, 2009
 
2) 中山壽之,他:肝細胞癌取扱い規約とTNM分類-日本と欧米の違い-.外科 74:131-135,2012
 
P.25 掲載の参考文献
1) 日本肝臓学会編:科学的根拠に基づく肝癌診療ガイドライン, 金原出版, 東京, 2009
 
2) Bruix J,et al:AASLD practice guideline management of hepatocellular carcinoma:an update.Hepatology 53:1020-1022,2011
 
P.28 掲載の参考文献
1) 飯島尋子:肝疾患の造影超音波診断-その変遷と新しい展開.肝臓 50:105-121,2009
 
2) Hayashi M,et al:Progression to hypervascular hepatocellular carcinoma:correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material.Radiology 225:143-149,2002
PubMed
3) 田中弘教,他:腫瘍性肝疾患の超音波診断.超音波医学 38:401-411,2011
Medical*Online
4) 田中弘教,他:肝腫瘍診断および治療支援における造影超音波の基礎-投与法,装置条件,時相.肝・胆・膵 60:355-362,2010
 
5) 田中弘教,他:Sonazoid造影超音波による新しい肝癌悪性度分類法の試み.肝臓 50:397-399,2009
 
P.30 掲載の参考文献
1) Cha C,et al:Predictors and patterns of recurrence after resection of hepatocellular carcinoma.J Am Coll Surg 197:753-758,2003
PubMed
2) Arii S,et al:Surgical strategies for hepatocellular carcinoma with special reference to anatomical hepatic resection and intraoperative contrast-enhanced ultrasonography.Oncology 78(Suppl 1):125-130,2010
 
3) Kishi Y,et al:Resection of segment VIII for hepatocellular carcinoma.Br J Surg 99:1105-1112,2012
PubMed
P.33 掲載の参考文献
1) 日本肝癌研究会編:第18回全国原発性肝癌追跡報告, 日本肝癌研究会事務局, 大阪, 2009
 
2) 日本肝癌研究会編:原発性肝癌取扱い規約, 第5版, 金原出版, 東京, 2008
 
3) Ikai I,et al:Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey.Cancer 101:796-802,2004
 
4) Nishie A,et al:Radiologic detectability of minute portal venous invasion in hepatocellular carcinoma.AJR Am J Roentgenol 190:81-87,2008
PubMed
5) 阿部光一郎,他:肝細胞癌の胆管浸潤に関するCT診断能. 日本医放会誌 55:659-662,1995
 
P.36 掲載の参考文献
1) Nishie A,et al:Radiologic detectability of minute portal venous invasion in hepatocellular carcinoma.AJR 190:81-87,2008
PubMed
2) Imaeda T,et al:Tumor thrombus in the branches of the distal portal vein:CT demonstration.J Comput Assist Tomogr 13:262-268,1989
PubMed
P.40 掲載の参考文献
1) Nishie A,et al:Radiologic detectability of minute portal venous invasion in hepatocellular carcinoma.AJR Am J Roentgenol 190:81-87,2008
PubMed
2) Shirabe K,et al:Predictors of microscopic portal vein invasion by hepatocellular carcinoma:measurement of portal perfusion defect area ratio.J Gastroenterol Hepatol 24:1431-1436,2009
PubMed
3) Ueda K,et al:Hypervascular hepatocellular carcinoma:evaluation of hemodynamics with dynamic CT during hepatic arteriography.Radiology 206:161-166,1998
PubMed
4) Sakon M,et al:Intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.Arch Surg 137:94-99,2002
PubMed
5) Nishie A,et al:Radiological assessment of hepatic vein invasion by hepatocellular carcinoma using combined computed tomography hepatic arteriography and computed tomography arterial portography.Jpn J Radiol 28:414-422,2010
PubMed
P.42 掲載の参考文献
1) Ikai I,et al:Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey.Cancer 101:796-802,2004
 
2) 伊在井淳子,他:経皮的ラジオ波焼灼治療後に門脈腫瘍栓が急速に進展した肝細胞癌の1例. 日消外会誌 38:1318-1323,2005
 
3) Imaeda T,et al:Tumor thrombus in the branches of the distal portal vein:CT demonstration.J Comput Assist Tomogr 13:262-268,1989
PubMed
P.44 掲載の参考文献
1) 日本肝癌研究会編:臨床・病理原発性肝癌取扱い規約, 第5版補訂版, 金原出版, 東京, 2009
 
2) Rossi S,et al:Contrast enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma.Eur Radiol 18:1749-1756,2008
PubMed
3) 工藤正俊,他:肝癌治療効果判定基準(2009年改訂版).肝臓 51:261-266,2010
 
P.46 掲載の参考文献
1) 日本肝癌研究会編:原発性肝癌取扱い規約, 第5版補訂版, 金原出版, 東京, 15,2009
 
2) Arii S,et al:Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas:a retrospective and nationwide survey in Japan.The Liver Cancer Study Group of Japan Hepatology 32:1224-1229,2000
 
P.48 掲載の参考文献
1) Makuuchi M,et al:Ultrasonically guided subsegmentectomy.Surg Gynecol Obstet 161:346-350,1985
PubMed
2) Ishizawa T,et al:Real-time identification of liver cancers by using indocyanine green fluorescent imaging.Cancer 115:2491-2504,2009
PubMed
3) Makuuchi M,et al:Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan.Hepatol Res 38:37-51,2008
PubMed
4) Kokudo N,et al:Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan:the J-HCC guidelines.J Gastroenterol 44(Suppl 19):119-121,2009
 
5) Kudo M,et al:Management of hepatocellular carcinoma in Japan:consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology(JSH)2010 updated version.Dig Dis 29:339-364,2011
PubMed
P.50 掲載の参考文献
1) Moore KP,et al:The management of ascites in cirrhosis:report on the consensus conference of the International Ascites Club.Hepatology 38:258-266,2003
PubMed
2) Runyon BA,et al:The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites.Ann Intern Med 117:215-220,1992
 
3) 福井博:難治性腹水の病態と治療. 日消誌 105:1597-1604,2008
Medical*Online
P.52 掲載の参考文献
1) Lautz HU,et al:Protein-calorie malnutrition in liver cirrhosis.Clin Investig 70:478-486,1992
PubMed
2) Tajika M,et al:Prognostic value of energy metabolism in patients with viral liver cirrhosis.Nutrition 18:229-234,2002
PubMed
3) Marchesini G,et al:Nutritional supplementation with branched-chain amino acids in advanced cirrhosis:a double-blind,randomized trial.Gastroenterology 124:1792-1801,2003
PubMed
4) Muto Y,et al:Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis.Clin Gastroenterol Hepatol 3:705-713,2005
PubMed
5) Fan ST,et al:Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma.N Engl J Med 331:1547-1552,1994
PubMed
P.56 掲載の参考文献
1) Papatheodoridis GV,et al:Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT:A systematic review.J Hepatol 57:196-202,2012
 
2) Yokosuka O,et al:Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection.J Hepatol 52:791-799,2010
PubMed
3) Chang TT,et al:Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.Hepatology 52:886-893,2010
PubMed
4) Shim JH,et al:Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis.J Hepatol 52:176-182,2010
PubMed
5) Manolakopoulos S,et al:Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.J Hepatol 51:468-474,2009
PubMed
P.62 掲載の参考文献
1) Hasegawa K,et al:Surgical resection vs.percutaneous ablation for hepatocellular carcinoma:a preliminary report of the Japanese nationwide survey.J Hepatol 49:589-594,2008
PubMed
2) Huang J,et al:A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria.Ann Surg 252:903-912,2010
 
3) Chen MS,et al:A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma.Ann Surg 243:321-328,2006
 
4) Feng K,et al:A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma.J Hepatol 57:794-802,2012
 
P.71 掲載の参考文献
1) Motosugi,U et al:Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease.J magn Reson Imaging 34:88-94,2011
PubMed
2) Kumada,T et al:Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI.AJR Am J Roentgenol 197:58-63,2011
PubMed
3) Management of hepatocellular carcinoma European Association for the Study of the Liver: EASL-EORTC Clinical Practice Guidelines.J Hepatol 56:j908-943,2012
 
4) Bruix,J et al:Management of hepatocellular carcinoma:an update.Hepatology 53:1020-1022,2011
PubMed
5) 幕内雅敏編:科学的根拠に基づく肝癌診療ガイドライン, 2005年版, 金原出版, 東京, 50-66,2005
 
P.76 掲載の参考文献
1) Shimada K,et al:A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy.Cancer 104:1939-1947,2005
PubMed
2) Poon RT,et al:Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma:a study of a prospective cohort.J Clin Oncol 19:3037-3044,2001
 
3) Eguchi S,et al:Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma;Liver Cancer Study Group of Japan.Br J Surg 98:552-557,2011
 
4) The Liver Cancer Study Group of Japan:General rules for the clinical and pathological study of primary liver cancer,4th ed,Kanehara&Co.,Ltd,Tokyo, 2000
 
5) Kokudo N,et al:Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan:the J-HCC guidelines.J Gastroenterol 44(Suppl 19):119-121,2009
 
P.83 掲載の参考文献
1) 緑川泰,他:治療アルゴリズムの東西.Liver Cancer J 3:195-199,2011
Medical*Online
2) 日本肝臓学会編:肝癌診療ガイドライン, 2009年版, 金原出版, 東京, 2009
 
3) Huang,J et al:A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria.Ann Surg 252:903-912,2010
 
4) 日本肝癌研究会:第18回全国原発性肝癌追跡調査報告(2004-2005).肝臓 51:460-484,2010
 
5) Hashimoto,T et al:Caval invasion by liver tumor is limited.J Am Coll Surg 207:383-392,2008
PubMed
P.91 掲載の参考文献
1) Lin SM,et al:Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma<or＝4cm.Gastroenterology 127:1714-1723,2004
 
2) Chen MS,et al:A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma.Ann Surg 243:321-328,2006
 
3) Lu MD,et al:Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma:a randomized clinical trial.Zhonghua Yi Xue Za Zhi 86:801-805,2006
PubMed
4) Shiina S,et al:Radiofrequency ablation for hepatocellular carcinoma:10-year outcome and prognostic factors.Am J Gastroenterol 107:569-577,2012
PubMed
P.98 掲載の参考文献
1) 日本肝臓病学会編:科学的根拠に基づく肝癌診療ガイドライン2009年版, 金原出版, 東京, 2009
 
2) Shiina S,et al:Radiofrequency ablation for hepatocellular carcinoma:10-year outcome and prognostic factors.Am J Gastroenterol 107:569-577,2012
PubMed
3) LlovetJM,et al:Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial.Lancet 359:1734-1739,2002
 
4) 幕内雅敏,他:肝硬変合併肝癌治療のstrategy.外科診療 29:1530-1536,1987
 
5) Imamura H,et al:One Thousand fifty-six hepatectomies without mortality in 8 years.Arch Surg 138:1198-1206,2003
PubMed
P.107 掲載の参考文献
1) 日本肝臓学会編:科学的根拠に基づく肝癌診療ガイドライン, 2009年版, 金原出版, 東京, 2009
 
2) Bruix,J et al:Chomoembolization for hepatocellular carcinoma.Gastroenterology 127:S179-188,2004
PubMed
3) Verela,M et al:Chomoembolization of hepatocellular carcinoma with drug eluting beads.J of Hepatol 46:474-481,2007
 
4) Obi,S et al:Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion.Cancer 106:1990-1997,2006
PubMed
P.115 掲載の参考文献
1) Nakao N,et al:Determination of the optimum dose level of lipiodol in transcatheter arterial embolization of primary hepatocellular carcinoma based on retrospective multivariate analysis.Cardiovasc Intervent Radiol 17:76-80,1994
PubMed
2) Takayasu K,et al:Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma.A propensity Score analysis.AJR Am J Roentgenol; 194:830-837,2010
PubMed
3) 日本肝癌研究会編:臨床・病理原発性肝癌取扱い規約, 第5版補訂版, 金原出版, 東京, 30-31,2009
 
4) Wang W,et al:Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma:a meta-analysis.Liver Int. 30:741-749,2010
PubMed
P.124 掲載の参考文献
1) 日本肝臓学会編:肝癌診療マニュアル, 第2版, 医学書院, 東京, 2010
 
2) Ando E,et al:Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis:analysis of 48 cases.Cancer 95:588-595,2002
PubMed
3) Obi S,et al:Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion.Cancer 106:1990-1997,2006
PubMed
4) 浦山直樹,他:進行肝細胞癌に対する肝動注化学療法114例の検討.肝臓 52:449-460,2011
 
5) 平峯靖也,他:高度進行肝細胞癌に対する肝動脈化学療法の検討. 日消誌 107:1127-1138,2010
Medical*Online
P.132 掲載の参考文献
1) 日本肝癌研究会編:肝癌取扱い規約, 第5版補訂版 ,金原出版, 東京, 17,2009
 
2) 日本肝癌研究会追跡調査委員会:第18回全国原発性肝癌追跡調査報告(2004-2005).肝臓 51:460-484,2010
 
3) Nakashima Y,et al:Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type.Hepatol Res 26:142-147,2003
PubMed
4) Sumie S,et al:Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors.Ann Surg Oncol 15:1375-1382,2008
PubMed
P.135 掲載の参考文献
1) Kumada T,et al:Clinical utility of lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma:special reference to imaging diagnosis.J Hepatol 30:125-130,1999
PubMed
2) Tada T,et al:Relationship between lens culinaris agglutinin-reactive a-fetoprotein and pathologic features of hepatocellular carcinoma.Liver Int 25:1-6,2005
 
P.138 掲載の参考文献
1) Asahina Y,et al:Laparoscopic radiofrequency ablation for hepatocellular carcinoma.Dig Endosc 21:67-72,2009
PubMed
P.143 掲載の参考文献
1) 日本肝臓学会編:科学的根拠に基づく肝癌診療ガイドライン, 2009年版, 金原出版, 東京, 13,2009
 
2) 日本肝臓学会編:肝癌診療マニュアル, 第2版, 医学書院, 東京, 2010
 
3) 日本肝癌研究会追跡調査委員会:第18回全国原発性肝癌追跡調査報告.肝臓 51:460-484,2010
 
4) 宮野正人,他:テガフール/ウラシル顆粒が著効したStage IVB(Vp3,肺転移)肝細胞癌の1例.癌と化学療法 37:1139-1143,2010
Medical*Online
5) 工藤正俊編:肝細胞癌の分子標的治療, アークメディア, 東京, 2010
 
P.146 掲載の参考文献
1) 池本哲也,他:拡大肝葉切除.手術 65:1875-1880,2011
 
2) 奥村仙示,他:肝硬変患者に対するテーラーメイド栄養管理の血液生化学指標についての検討.栄養-評価と治療 28:18-20,2011
Medical*Online
3) Ogasawara T,et al:Influence of Dai-kenchu-to (DKT) on human portal blood flow.Hepato gastroentero logy 55:574-577,2008
 
4) 宇都宮徹,他:保険収載後の腹腔鏡下肝切除術の展開.消化器外科 34:69-77,2011.
 
5) Yamada S,et al:Outcome of hepatectomy in super-elderly patients with hepatocellular carcinoma.Hepatol Res 42:454-458,2012
PubMed
P.148 掲載の参考文献
1) 日本肝臓学会編:科学的根拠に基づく肝癌診療ガイドライン, 2009年版, 金原出版, 東京, 2009
 
2) 日本肝臓学会編:肝癌診療マニュアル, 第2版, 医学書院, 東京, 2010
 
3) 辻邦彦,他:高齢者肝細胞癌に対する臨床的検討-RFAの有用性も含めて-. 日高齢消医会誌 10:43-46,2008
 
P.150 掲載の参考文献
1) Tateishi R,et al:Percutaneous radiofrequency ablation for hepatocellular carcinoma.An analysis of 1000 cases.Cancer 103:1201-1209,2005
PubMed
2) Baigent C,et al:Aspirin in the primary and secondary prevention of vascular disease:collaborative meta-analysis of individual participant data from randomised trials.Lancet 373:1849-1860,2009
PubMed
3) Tsan YT,et al:Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection.J Clin Oncol 30:623-630,2012
PubMed
4) Biondi-Zoccai GG,et al:A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease.Eur Heart J 27:2667-2674,2006
PubMed
5) Park SJ,et al:Duration of dual antiplatelet therapy after implantation of drug-eluting stents.N Engl J Med 362:1374-1382,2010
PubMed
P.153 掲載の参考文献
1) 小原勝敏,他:食道・胃静脈瘤内視鏡治療ガイドライン.日本消化器内視鏡学会卒後教育委員会(編):消化器内視鏡ガイドライン, 第3版, 医学書院, 東京, 215-233,2006
 
2) Garcia-Taso G,et al:Portal hypertension and variceal bleeding;unresolved issues;summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference.Hepatology 47:1764-1772,2008
 
3) 日本門脈圧亢進症学会(編),門脈圧亢進症取扱い規約, 改訂第2版, 金原出版, 東京, 37-39,2004
 
4) 佐野圭二:付加手術としてのHassab手術.幕内雅敏,高山忠利(編):肝臓外科の要点と盲点, 第2版, 文光堂, 東京, 188-189,2006
 
P.155 掲載の参考文献
1) 高山忠利,他:脾機能亢進症合併肝細胞癌症例に対する脾臓摘出術の臨床的意義-とくに肝切除適応拡大との関連から-.日外会誌 90:1043-1048,1989
 
2) Shimada M,et al:A new surgical strategy for cirrhotic patients with hepatocellular carcinoma and hypersplenism.Performing a hepatectomy after a laparoscopic splenectomy.Surg Endosc 14:127-130,2000
PubMed
3) Sugawara Y,et al:Splenectomy in patients with hepatocellular carcinoma and hypersplenism.J Am Coll Surg 190:446-450,2000
PubMed
4) Chen XP,et al:Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism.Br J Surg 92:334-339,2005
PubMed
5) 吉留博之,他:肝硬変合併肝細胞癌における術前PSEの有用性.臨外 64:453-457,2009
 
P.165 掲載の参考文献
1) Imamura H,et al:Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.J Hepatol 38:200-207,2003
PubMed
2) Shimada M,et al:Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma.Ann Surg 227:80-85,1998
PubMed
3) Imamura H,et al:Sequential TACE and PVE for HCC.Madoff DC,et al(eds):Venous Embolization of the Liver:Radiological and Surgical Practice,1st ed,Springer,London, 249-250,2011
 
4) Nakayama A,et al:Value of lipiodol computed tomography and digital subtraction angiography in the era of helical biphasic computed tomography as preoperative assessment of hepatocellular carcinoma.Ann Surg 34:56-62,2001
 
P.170 掲載の参考文献
1) Ikai I,et al:Report of the 18th follow-up survey of primary liver cancer in Japan.Hepatol Res 40:1043-1059,2010
PubMed
2) Ishikawa T,et al:Comination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival.Hepatogastroenterology 59:529-532,2012
 
3) Ishikawa T,et al:Prevention of intrahepatic distant recurrence by transcatheter arterial infusion chemotherapy with platinum agents for Stage I／II hepatocellular carcinoma.Cancer 117:4018-4025,2011
 
4) Ishikawa T,et al:Oral branched-chain amino acids administration improves impaired liver dysfunction after radiofrequency ablation therapy for Hepatocellular Carcinoma.Hepatogastroenterology 56:1491-1495,2009
PubMed
5) Ishikawa T,et al:Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma.J Gastroenterol Hepatol 16:452-459,2001
 
P.177 掲載の参考文献
1) 日本肝臓学会編:科学的根拠に基づく肝癌診療ガイドライン, 2009年版, 金原出版, 東京, 2009
 
P.180 掲載の参考文献
1) 日本肝臓学会編:科学的根拠に基づく肝癌診療ガイドライン, 2009年版, 金原出版, 東京, 2009
 
2) 日本肝臓学会編:肝癌診療マニュアル,第2版, 医学書院, 東京, 2010
 
P.186 掲載の参考文献
1) Yang Y,et al:Pattern and clinicopathlogic feature of extrahepatic recurrence of hepatocelluar caricinoma after curative resection.Surgery 141:196-202,2009
 
2) Tomimaru Y,et al:The significance of surgical resection for pulmonary metastasis from hepatocelluar carcinoma.Am J Surg 192:46-51,2006
 
3) Cheng A,et al:Efficacy and safety of sorafenib in patients with hepatocellular carcinoma according to baseline status:Subset analysis of the phase three Sorafenib Asia-Pasific trial.E J Cancer 2012 in press
 
4) Otsuka T,et al:Prognosis of hepatocellular carcinoma patients with extrahepatic metastases.Hepatogastroenterology 44:251-257,1997
 
5) Yamakado K,et al:Adrenal metastasis from hepatocellular carcinoma:radiofrequency ablation combined with adrenal arterial chemoembolization in six patients.AJR 192:300-305,2009
 
P.190 掲載の参考文献
1) 岡博子,他:多施設(22施設)調査に基づく肝癌無治療例195例の検討.肝臓 46:546-551,2003
 
2) 近藤祐嗣,他:非代償性肝硬変に合併した肝臓癌治療の工夫.肝胆膵 50:725-729,2005
Medical*Online
3) 豊田秀徳,他:非代償性肝硬変の予後に対する肝細胞癌インパクトと治療の意義.消化器科 41:345-351,2005
 
4) 進藤邦明,他:非代償性肝硬変の生命予後に関与する因子の検討.消化器科 54:333-339,2012
 
5) 熊田博光:平成23年B 型C型慢性肝炎・肝硬変治療のガイドライン.
 
P.192 掲載の参考文献
1) Hasegawa K,et al:Uracil-tegafur as an adjuvant for hepatocellular carcinoma:a randomized trial.Hepatology 44:891-895,2006
PubMed
2) Takayama T,et al:Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma:a randomised trial.Lancet 356:802-807,2000
PubMed
3) Llovet JM,et al:Sorafenib in advanced hepatocellular carcinoma.N Engl J Med 359:378-390, 2008
PubMed
4) Muto Y,et al:Prevention of second primary tumors by an acyclic retinoid,polyprenoic acid,in patients with hepatocellular carcinoma.Hepatoma Prevention Study Group.N Engl J Med 334:1561-1567,1996
 
5) Kubo S,et al:Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma.A randomized,controlled trial.Ann Intern Med 134:963-967,2001
 
P.197 掲載の参考文献
1) 日本肝臓学会編:科学的根拠に基づく肝癌診療ガイドライン, 2009年版, 金原出版, 東京, 2009
 
2) Hasegawa K,et al:Comparison of resection and ablation for hepatocellular carcinoma:a cohort study based on a Japanese nationwide survey.J Hepatol 2013,http://dx.doi.org/10.1016/j.jhep.2012.11.009
 
3) 日本肝移植研究会:肝移植症例登録報告.移植 46:524-536,2011
Medical*Online
4) 幕内雅敏,他:肝硬変合併肝癌治療のStrategy.外科診療 29:1198-1206,1987
 
5) Bruix J,et al:Prognostic prediction and treatment strategy in hepatocellular carcinoma.Hepatology 35:519-524,2002
PubMed
P.201 掲載の参考文献
1) Makuuchi M,et al:Ultrasonically guided subsegmentectomy.J Surg Gynecol Obstet 161:346-350,1985
 
2) 高山忠利:ペアンによる肝離断.幕内雅敏,他編:Knack&pitfalls 肝臓外科の要点と盲点, 第2版, 文光堂, 東京, 152-153,2006
 
P.204 掲載の参考文献
1) Takayama T,et al:Randomized comparison of ultrasonic vs clamp transection of the liver.Arch Surg 136:922-928,2001
PubMed
2) Saiura A,et al:Usefulness of LigaSure for liver resection:analysis by randomized clinical trial.Am J Surg 192:41-45,2006
PubMed
3) Yamamoto Y et al:New simple technique for hepatic parenchymal resection using a Cavitron Ultrasonic Surgical Aspirator and bipolar cautery equipped with a channel for water dripping.World J Surg 23:1032-1037,1999
PubMed
4) Sakamoto Y,et al:Bloodless liver resection using the monopolar floating ball plus ligasure diathermy:preliminary results of 16 liver resections.World J Surg 28:166-172,2004
PubMed
5) Nakajima Y,et al:Control of intraoperative bleeding during liver resection:analysis of a questionnaire sent to 231 Japanese hospitals.Surg Today 32:48-52,2002
PubMed
P.206 掲載の参考文献
1) Makuuchi M,et al:Intraoperative ultrasonic examination for hepatectomy.Ultrasound Med Biol 9(Suppl 2):471-475,1983
 
2) Kokudo N,et al: Management of new hepatic nodules detected by intraoperative ultrasonography during hepatic resection for hepatocellular carcinoma.Surgery 119:634-640,1996
PubMed
3) Arita J,et al:Usefulness of contrast-enhanced intraoperative ultrasound using Sonazoid in patients with hepatocellular carcinoma.Ann Surg Oncol 14:1347-1355,2007
 
4) Makuuchi M,et al:Ultrasonically guided subsegmentectomy.Surg Gynecol Obstet 161:346-350,1985
PubMed
P.210 掲載の参考文献
1) Makuuchi,M et al:Ultrasonically guided subsegmentectomy.Surg Gynecol Obstet 161:346-350,1985
PubMed
2) Takayama,T et al:High dorsal resection of the liver.J Am Coll Surg 179:72-75,1994
 
3) Takayama,T et al:A new method for mapping hepatic subsegment:counterstaining identification technique.Surgery 109:226-229,1991
PubMed
4) Takayama,T et al:Randomized comparison of ultrasonic vs clamp transection of the liver.Arch Surg 136:922-928,2001
PubMed
P.213 掲載の参考文献
1) Kaneko H,et al:Laparoscopic liver resection of hepatocellular carcinoma.Am J Surg 189:190-194,2005
PubMed
2) Kaneko H,et al:Laparoscopic partial hepatectomy and left lateral segmentectomy:technique and results of a clinical series.Surgery 120:468-475,1996
PubMed
3) Buell JF,et al:The international position on laparoscopic liver surgery.The Louisville Statement,2008.Ann Surg 250:825-830,2009
PubMed
4) Kaneko H,et al:Laparoscopic hepatectomy for hepatocellular carcinoma in cirrhotic patients.J Hepatobiliary Pancreat Surg 16:33-438,2009
 
P.216 掲載の参考文献
1) Wakabayashi G:Laparoscopic liver resection:how far can we go? J Hepatobiliary Pancreat Surg 16:403-404,2009
 
2) Rao A,et al:Laparoscopic or open liver resection? Let systematic review decide it.Am J Surg 204:222-231,2012
 
3) Nitta H,et al:Laparoscopy-assisted major liver resections employing a hanging technique:the original procedure.Ann Surg 251:450-453,2010
PubMed
4) http://www.drstyle.tv/lpd/0058/01.html
 
P.220 掲載の参考文献
1) Imamura H,et al:One Thousand fifty-six hepatectomies without mortality in 8 years.Arch Surg 138:1198-1206,2003
PubMed
2) Llovet JM,et al:Hepatocellular carcinoma.Lancet 362:1907-1917,2003
PubMed
3) Ishizawa T,et al:Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.Gastroenterology 134:1908-1916, 2008
PubMed
4) Nonami T,et al:Blood loss and ICG clearance as best prognostic maker of post-hepatectomy liver failure.Hepatogastroenterol 46:1669-1672,1999
 
5) Kubota K,et al:Measurement of liver volume and function reserve as a guide to decision-making in resectional surgery for hepatic tumors.Hepatology 26:1176-1181,1997
PubMed
P.223 掲載の参考文献
1) 幕内雅敏,他:胆管癌に対する肝切除前肝内門脈枝塞栓術.日臨外会誌 45:1558-1564,1984
 
2) Makuuchi M,et al:Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma:a preliminary report.Surgery 107:521-527,1990
PubMed
3) 幕内雅敏,他:肝臓外科の要点と盲点 ,第2版, 文光堂, 東京, 218-222,2006
 
4) Kubota K,et al:Measurement of the liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors.Hepatoloy 26:1176-1181,1997
 
5) Shimamura T,et al:Efficacy and safety of preoperative percutaneous transhepatic portal embolization with absolute ethanol;a clinical study.Surgery 121:135-141,1997
PubMed
P.227 掲載の参考文献
1) 今村宏,他:肝切除の命名法.幕内雅俊,他編:Knack&Pitfalls 肝臓外科の要点と盲点,第2版, 文光堂, 東京, 238-239,2006
 
2) Kosuge T,et al:An isolated complete resection of the caudate lobe,including the paracaval portion,for hepatocellular carcinoma.Arch Surg 129:280-284,1994
PubMed
3) Takayama T,et al:High dorsal resection of the liver.J Am Coll Surg 179:72-75,1994
 
4) 川崎誠治:左傍正中領域切除(S3＋S4切除).幕内雅俊,他編:Knack&Pitfalls 肝臓外科の要点と盲点, 第2版, 文光堂, 東京, 278-279,2006
 
5) 小菅智男:下右肝静脈温存手術.幕内雅俊,他編:Knack&Pitfalls 肝臓外科の要点と盲点, 第2版, 文光堂, 東京, 280-282,2006
 
P.230 掲載の参考文献
1) Miyazaki M,et al:Aggressive surgical resection for hepatic metastases involving the inferior vena cava.Am J Surg 177:294-298,1999
PubMed
2) Miyazaki M,et al:Portal vein reconstruction at the hepatic hilus using a left renal vein graft.J Am Coll Surg 180:497-498,1995
 
3) Suzuki T,et al:Renal function is well maintained after use of left renal vein graft for vascular reconstruction in hepatobiliary-pancreatic surgery.J Am Coll Surg 202:87-92,2006
PubMed
4) Yoshidome H,et al:Should the inferior vena cava be reconstructed after resection for malignant tumors? Am J Surg 189:419-424,2005
PubMed
5) Miyazaki M,et al:Hepatic vein reconstruction using autologous vein graft for resection of advanced hepatobiliary malignancy.Hepatogastroenterology 51:1581-1585,2004
PubMed
P.234 掲載の参考文献
1) http://www.jcog.jp/doctor/tool/Clavien_Dindo.html
 
2) Ishizawa T,et al:Risk factors and management of ascites after liver resection to treat hepatocellular carcinoma.Arch Surg 144:46-51,2009
PubMed
3) Koch M,et al:Bile leakage after hepatobiliary and pancreatic surgery:a definition and grading of severity by the International Study Group of Liver Surgery.Surgery 149:680-688,2011
 
4) Yoshioka R,et al:Predictive factors for bile leakage after hepatectomy:analysis of 505 consecutive patients.World J Surg 35:1898-1903,2011
PubMed
5) Rahbari NN,et al:Posthepatectomy liver failure:a definition and grading by the International Study Group of Liver Surgery(ISGLS).Surgery 149:713-724,2011
 
P.238 掲載の参考文献
1) Uemura M, et al:Surgery for hepatocellular carcinoma with tumor thrombus extending into the right atrium:report of a successful resection without the use of cardiopulmonary bypass.Hepato-gastroenterology 51:1259-1262,2004
PubMed
P.242 掲載の参考文献
1) 山中若樹,他:肝切除後における異時性多中心性発癌と肝内転移再発について.肝胆膵 36:219-225,1998
 
2) 山中若樹,他:多発肝癌に対する肝切除術を組み入れた集学的治療戦略.日本臨床 59:717-720,2001
 
3) 日本肝臓学会編:肝癌診療マニュアル, 第2版, 医学書院, 東京, 125,2010
 
4) 日本肝癌研究会編:第18回全国原発性肝癌追跡調査報告(2004-2005).肝臓 51:460-484,2010
 
5) 山中若樹,他:肝切除を軸とした集学的治療.臨床消化器内科 14:29-33,1999
 
P.245 掲載の参考文献
1) Selle D,et al:Analysis of vasculature for liver surgical planning.IEEE Trans Med Imaging 21:1344-1357,2002
PubMed
2) Saito S,et al:A novel 3D hepatectomy simulation based on liver circulation:application to liver resection and transplantation.Hepatology 41:1297-1304,2005
PubMed
3) Makuuchi M,et al:Surgery for small liver cancers.Semin Surg Oncol 9:298-304,1993
PubMed
4) Mise Y,et al:Venous reconstruction based on virtual liver resection to avoid congestion in the liver remnant.Br J Surg 98:1742-1751,2011
PubMed
P.248 掲載の参考文献
1) Ong GB,et al:Spontaneous rupture of hepatocellular carcinoma.Br J Surg 52: 123-129,1965
PubMed
2) Liu CL,et al:Management of spontaneous rupture of hepatocellular carcinoma:single-center experience.J Clin Oncol 19:3725-3732,2001
 
3) Chen CY,et al:Spontaneous rupture of hepatocellular carcinoma:a review of 141 Taiwanese cases and comparison with nonrupture cases.J Clin Gastroenterol 21:238-242,1995
 
4) Zhu LX,et al:Spontaneous rupture of hepatocellular carcinoma.Br J Surg 83:602-607,1996
PubMed
5) Aoki T,et al:Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma:an analysis of 1,160 cases from a nation-wide survey.Ann Surg(in press).
 
P.250 掲載の参考文献
1) 日本肝癌研究会編:原発性肝癌取扱い規約, 第5版補訂版, 金原出版, 東京, 2009
 
2) American Joint Committee on Cancer:AJCC Cancer Staging Manual,7th ed,Springer,New York, 2010
 
3) Uenishi T,et al:The clinical significance of lymph node metastases in patients undergoing surgery for hepatocellular carcinoma.Surg Today 30:892-895,2000
PubMed
4) Lee CW,et al:Hepatic resection for hepatocellular carcinoma with lymph node metastasis:clinicopathological analysis and survival outcome.Asian J Surg 34:53-62,2011
PubMed
5) 長谷川潔,他(日本肝癌研究会):肝細胞癌リンパ節転移切除の長期成績:全国データに基づく検討.第47回日本肝癌研究会抄録集, 263,2011
 
P.252 掲載の参考文献
1) 日本肝癌研究会編:第18回全国原発性肝癌追跡調査報告(2004-2005), 日本肝癌研究会事務局, 大阪, 2009
 
2) Midorikawa Y,et al:Marginal survival benefit in the treatment of early hepatocellular carcinoma.J Hepatol 58:306-311,2013
PubMed
3) Minagawa M et al:Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma.Ann Surg 238:703-710,2003
PubMed
4) Yamazaki S,et al:Criteria for drain removal following liver resection.Br J Surg 99:1584-1590,2012
PubMed
5) Ishizawa T,et al:Risk factors and management of ascites after liver resection to treat hepatocellular carcinoma.Arch Surg 144:46-51,2009
PubMed
P.255 掲載の参考文献
1) Ishizawa T,et al:Real-time identification of liver cancers by using indocyanine green fluorescent imaging.Cancer 115:2491-2504,2009
PubMed
2) Harada N,et al:Fluorescence navigation hepatectomy by visualization of localized cholestasis from bile duct tumor infiltration.J Am Coll Surg 210:e2-e6, 2010
PubMed
3) Aoki T,et al:Image-guided liver mapping using fluorescence navigation system with indocyanine green for anatomical hepatic resection.World J Surg 32:1763-1767,2008
PubMed
4) 石沢武彰,Brice Gayet:Gayet腹腔鏡下肝胆膵手術, 南江堂, 東京, 2012
 
5) Ishizawa T,et al:Positive and negative staining of hepatic segments by use of fluorescent imaging techniques during laparoscopic hepatectomy.Arch Surg 147:393-394,2012
PubMed
P.257 掲載の参考文献
1) Sangiovanni A,et al:Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance.Gastroenterology 126:1005-1014,2004
PubMed
2) Takayama T,et al:Early hepatocellular carcinoma as an entity with a high rate of surgical cure.Hepatology 28:1241-1246,1998
PubMed
3) Kafadar K,et al:A data-analytic approach for estimating lead time and screening benefit based on survival curves in randomized cancer screening trials.Stat Med 13:569-586,1994
 
4) Mark DB,et al:Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.N Engl J Med 332:1418-1424,1995
PubMed
5) Midorikawa Y,et al:Marginal survival benefit in the treatment of early hepatocellular carcinoma.J Hepatol 58:306-311,2013
PubMed
P.261 掲載の参考文献
1) Goldberg SN,et al:Radiofrequency tissue ablation:importance of local temperature along the electrode tip exposure in determining lesion shape and size.Acad Radiol 3:212-218,1996
PubMed
2) Goldberg SN,et al:Thermal ablation therapy for focal malignancy:a unified approach to underlying principles,techniques,and diagnostic imaging guidance.AJR Am J Roentgenol 174:323-331,2000
PubMed
3) Patterson EJ,et al:Radiofrequency ablation of porcine liver in vivo:effects of blood flow and treatment time on lesion size.Ann Surg 227:559-565,1998
PubMed
P.265 掲載の参考文献
1) 國分茂博:RFA3機種の特徴と使い分け.大崎往夫編:肝癌ラジオ波凝固療法の実践テクニック, 中山書店, 東京, 14-21,2008
 
2) Kobayashi M,et al:Stepwise hook extension technique for radiofrequency ablation therapy of hepatocellular carcinoma.Oncology 63:139-144,2002
PubMed
3) 日高央,他:経皮的ラジオ波熱凝固療法時の工夫-穿刺針が描出困難時のair beamの活用-.Rad Fan 4:104-106,2006
 
4) Nakazawa T,et al:Radiofrequency ablation of hepatocellular carcinoma:correlation between local tumor progression after ablation and ablative margin.AJR Am J Roentgenol 188:480-488.2007
PubMed
P.270 掲載の参考文献
1) 森安史典:肝癌ラジオ波治療の最前線大型肝癌のラジオ波治療.肝臓 46:185-190,2005
 
2) Kobayashi M,et al:Stepwise hook extension technique for radiofrequency ablation therapy of hepatocellular carcinoma.Oncology 63:139-144,2002
PubMed
P.276 掲載の参考文献
1) Shiina S,et al:A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.Gastroenterology 129:122-130,2005
PubMed
2) Tateishi R,et al:Percutaneous radiofrequency ablation for hepatocellular carcinoma.An analysis of 1000 cases.Cancer 103:1201-1209,2005
PubMed
3) 小池幸宏,他:転移性肝癌の治療戦略切除不能59症例に対するラジオ波焼灼療法の治療成績.肝臓 (0451-4203)45(Suppl 2):A414
 
4) Koike Y:Impact of radio-frequency ablation for unresectable hepatic metastases.日消誌 106:1421-1427,2009
 
5) 椎名秀一朗編:動画で学ぶ肝癌ラジオ波焼灼療法の実際, 医学書院, 東京, 2009
 
P.281 掲載の参考文献
1) 杉浦信之,他:超音波映像下経皮的腫瘍内エタノール注入による小肝細胞癌の治療.肝臓 24:920-923,1983
 
2) Seki T,et al:Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma.Cancer 74:817-825,1994
PubMed
3) Rossi S,et al:Percutaneous ultrasound-guided radiofrequency electrocautery for the treatment of small hepatocellular carcinoma.J Intervent Radiology 8:97,1993
 
4) 椎名秀一朗,他:Cool-tip型電極を用いた経皮的ラジオ波焼灼療法による肝細胞癌の治療.肝臓 41:24-30,2000
 
5) 大崎往夫,他:肝細胞癌に対する経皮的ラジオ波熱凝固療法(RFA)の検討.肝臓 42:22-28,2001
 
P.287 掲載の参考文献
1) 萩澤良美,他:Cool-tip 電極使用によるRFA2段階焼灼法.医学と薬学 54:163-165,2005
Medical*Online
2) Wakui N,et al:Cool-tip 10-mm Electrode Useful for Radiofrequency Ablation of Hepatocellular Carcinoma.Hepato-Gastroenterology 56:1585-1591,2009
PubMed
3) Yamasaki T,et al:Percutaneous radiofrequency ablation with cooled electrodes combined with hepatic arterial balloon occlusion in hepatocellular carcinoma.J Gastroenterol 40:171-178,2005
PubMed
4) 高山竜司,他:Cool-tip20mm電極針を用いた穿刺・通電方法の工夫-RFA焼灼範囲のさらなる拡大は可能か? -.医学と薬学 63:228-231,2010
Medical*Online
5) 高橋政義,他:肝細胞癌ラジオ波焼灼療法の焼灼範囲とSonazoid造影超音波後血管相(Kupffer phase)におけるmicro bubble崩壊距離との関係.Jpn J Med Ultrasonics 38:637-646,2011
 
P.290 掲載の参考文献
1) Lu,MD et al:Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma:randomized clinical trial.Zhonghua Yi Xue Za Zhi 28:801-805,2006
 
2) Chen,MS et al:Comparison of effects of percutaneous radiofreqency ablation and surgical resection on small hepatocellular carcinoma.Zhonghua Yi Xue Za Zhi 12:80-83,2005
 
3) Livraghi,T et al:Sustained complete response and complications rates after radiofreqency ablation of very early hepatocellular carcinoma in cirrhosis:Is resection still the treatment of choice? Hepatology 47:82-89,2008
 
4) Tang,Z et al:Percutaneous radiofrequency ablation for liver tumors:Is it safer and more effective in low-risk areas than in high-risk areas? Hepatology Research 41:635-640,2011
PubMed
5) Takahashi,H et al:Efficacy and safety of radio frequency ablation for elderly hepatocellular carcinoma patients.Hepatol Res 40:997-1005,2010
PubMed
P.294 掲載の参考文献
1) 春日井博司,他:多施設(38施設)調査に基づくラジオ波治療の現状と問題点.肝臓 44:632-640,2003
 
2) 泉並木:合併症とその頻度-アンケート調査の結果から.動画でわかる肝癌ラジオ波凝固療法の実践テクニック,中山書店,東京, 38-42,2008
 
3) Kondo Y,et al:Artificial ascites technique for percutaneous radiofrequency ablation of liver cancer adjacent to the gastrointestinal tract.Br J Surg 93:1277-1282,2006
 
4) Nagae G,et al:Laparoscopic ablation therapy for hepatocellular carcinoma.Dig Endosc 17:1-8,2005
 
5) 西村守,他:内視鏡的経鼻胆管ドレナージによる胆管クーリング下ラジオ波焼灼療法の臨床的検討.肝臓 47:123-128,2006
 
P.298 掲載の参考文献
1) 石川隆,他:横隔膜直下の肝細胞癌に対する人工胸水を用いた経皮的ラジオ波焼灼療法.肝臓 42:690-690,2001
 
2) 梅田尚季,他:Sonazoid造影下ラジオ波焼灼術の有用性とその適応.医学と薬学 59:203-205,2008
Medical*Online
3) 大崎往夫,他:Multi-phaseRVS下RFA.肝胆膵画像 10:211-219,2008
 
4) Noguchi O,et al:Laparoscopic ablation therapy for hepatocellular carcinoma.Clinical significance of a newly developed laparoscopic sector ultrasonic probe.Dig Endosc 15:179-184,2003
 
P.302 掲載の参考文献
1) Kunishi Y,et al:Efficacy of fusion imaging combining ultrasonography and hepatobiliary phase of contrast-enhanced MR image with gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid for detecting small hepatocellular carcinoma.AJR Am J Roentgenol 198:106-114,2012
PubMed
2) Korenaga K,et al:Usefulness of Sonazoid contrast-enhanced ultrasonography for hepatocellular carcinoma:comparison with pathological diagnosis and superparamagnetic iron oxide magnetic resonance images.J Gastroenterol 44:733-741,2009
PubMed
3) Kudo M,et al:Newly developed novel ultrasound technique,defect reperfusion ultrasound imaging,using sonazoid in the management of hepatocellular carcinoma.Oncology 78 S1:40-45,2010
 
4) Numata K,et al:Contrast-enhanced ultrasound of hepatocellular carcinoma.World J Radiol 2:68-82,2010
PubMed
5) Numata K,et al:Ablation therapy guided by contrast-enhanced sonography with Sonazoid for hepatocellular carcinoma lesions not detected by conventional sonography.J Ultrasound Med 27:381-392,2008
 
P.304 掲載の参考文献
1) 松居剛志,他:Volume-Dataを用いた肝癌に対するRFA.IVR 27:20-25,2012
 
P.306 掲載の参考文献
1) Llovet JM,et al:Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma.Hepatology 33:1124-1129,2001
PubMed
2) Teratani T,et al:Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations.Hepatology 43:1101-1108,2006
PubMed
3) Imamura J,et al:Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma,Am J Gastroenterol 103:3057-3062,2008
PubMed
4) Asahina Y,et al:Laparoscopic radiofrequency ablation for hepatocellular carcinoma.Dig Endosc 21:67-72,2009
PubMed
P.309 掲載の参考文献
1) Nishikawa H,et al:Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma:a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation.J Gastroenterol 46:1418-1426,2011
PubMed
2) Morimoto M,et al:Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma:a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization.Cancer 116:5452-5460,2010
PubMed
3) Yamakado K,et al:Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma:treatment response based on tumor size and morphology.J Vasc Interv Radiol 13:1225-1232,2002
PubMed
4) Shibata T,et al:Small hepatocellular carcinoma:is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 252:905-913,2009
PubMed
5) Kagawa T,et al:Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma:comparison with surgical resection.Cancer 116:3638-3644,2010
PubMed
P.313 掲載の参考文献
1) Kudo M:Radiofrequency ablation for hepatocellular carcinoma:updated review in 2010.Oncology 78(Suppl 1):113-124, 2010
 
P.318 掲載の参考文献
1) Pelletier G,et al:A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.J Hepatol 11:181-184,1990
 
2) Groupe d'Etude et de traitement du carcinoma hepatocellulaire:A comparison of chemopembolization and conservative treatment for unresectable hepatocellular carcinoma.N Engl J Med 332:1256-1261,1995
 
3) Bruix J,et al:Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma:results of a randomized controlled trial in a single institution.Hepatology 27:1578-1583,1998
 
4) Llovet JM,et al:Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomized controlled trial.Lancet 359:1734-1739,2002
 
5) Lo CM,et al:Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.Hepatology 35:1164-1171,2002
PubMed
P.320 掲載の参考文献
1) Nakamura H,et al:Accessory left gastric artery arising from left hepatic artery:angiographic study.AJR 134:529-532,1980
PubMed
2) Nakamura H,et al:Newly deviced long sheath for transfemoral angiography.Radiology 155:828,1985
 
P.322 掲載の参考文献
1) 神野健二,他:肝細胞癌におけるLipiodolの選択的腫瘍内停滞に関する臨床的・病理形態学的研究.肝臓 27:471-479,1986
 
2) Yamada R,et al:Hepatic artery embolization in 120 patients with unresectable hepatoma.Radiology 148:397-401,1983
PubMed
3) Hironobu N,et al:Transcatheter oily chemoembolization of hepatocellular carcinoma.Radiology 170:783-786,1989
 
4) Nishimine K,et al:Segmental transarterial chemoembolization with Lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma:follow-up CT and therapeutic results.Cancer Chemother Pharmacol 33(Suppl):S60-68,1994.
 
5) 是枝ちづ:肝細胞癌に対するLipiodol-TAE療法の抗腫瘍効果の検討.肝臓 31:636-646,1990
 
P.325 掲載の参考文献
1) Laurent A,et al:Trisacryl gelatin microspheres for therapeutic embolization,I:Development and in vitro evaluation.AJNR Am J Neuroradiol 17:533-540,1996
PubMed
2) Maluccio MA,et al:Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma.J Vasc Interv Radiol 19:862-869,2008
 
3) Malagari K,et al:Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with Bead-Block for hepatocellular carcinoma.Cardiovasc Intervent Radiol 33:541-551,2010
 
4) Lammer J,et al:Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma:results of the PRECISION V study.Cardiovasc Intervent Radiol 33:41-52,2010
PubMed
5) Burrel M,et al:Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization(TACE)using Drug Eluting Beads.Implications for clinical practice and trial design.J Hepatol 56:1330-1335,2012
PubMed
P.328 掲載の参考文献
1) Sahara S,et al:Prospective comparison of transcatheter arterial chemoembolization with Lipiodol-epirubicin and Lipiodol-cisplatin for treatment of recurrent hepatocellular carcinoma.Jpn J Radiol 28:362-368,2010
PubMed
2) Kasai K,et al:Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma.World J Gastroenterol 16:3437-3444,2010
PubMed
3) Yodono H,et al:A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma.Anticancer Drugs 22:277-282,2011
PubMed
4) Okabe K,et al:Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization(TACE)for hepatocellular carcinoma.Anticancer Res 31:2983-2988,2011
PubMed
5) Miyayama S,et al:Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma.Jpn J Radiol 30:263-270,2012
PubMed
P.330 掲載の参考文献
1) Takayasu K,et al:Superselective transarterial chemoembolization for hepatocellular carcinoma.Validation of treatment algorithm proposed by Japanese guidelines.J Hepatol 56:886-892,2012
PubMed
2) Takayasu K,et al:Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131:461-469,2006
PubMed
3) Takayama T:Hepatocellular carcinoma.Clavien PA,ed:Malignant liver tumors:Current and emerging therapies,3rd ed,Wiley-Blackwell,London, 317-323,2010
 
4) Takayasu K,et al:Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system:analysis of factors affecting local recurrence and survival rates.AJR Am J Roentgenol 176:681-688.2001
PubMed
5) Miyayama S,et al:Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas:relationship between local tumor recurrence and visualization of the portal vein with iodized oil.J Vasc Interv Radiol 18:365-376,2007
PubMed
P.333 掲載の参考文献
1) 日本肝臓学会編:肝癌診療ガイドライン, 2009年版, 金原出版, 東京, 12-13,2009
 
2) Takayasu K,et al:Liver Cancer Study Group of Japan:Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.Gastroenterology 131:461-469,2006
 
3) Miyayama S,et al:Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas:relationship between local tumor recurrence and visualization of the portal vein with iodized oil.J Vasc Interv Radiol 18:365-376,2007
PubMed
4) Sasaki A,et al:Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma.Cancer 103:299-306,2005
PubMed
5) Yodono H,et al:A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma.Anticancer Drugs 22:277-282,2011
PubMed
P.335 掲載の参考文献
1) 日本肝臓学会編:肝癌診療ガイドライン, 2009年版, 金原出版, 東京, 12-13,2009
 
2) Yamakado K,et al:Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma:treatment response based on tumor size and morphology.J Vasc Interv Radiol 13:1225-1232,2002
PubMed
3) Georgiades CS,et al:Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis.J Vasc Interv Radiol 16:1653-1659,2005
PubMed
4) Chern MC,et al:Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors.Cardiovasc Intervent Radiol 31:735-744,2008
PubMed
5) Takayasu K,et al:Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system:analysis of factors affecting local recurrence and survival rates.Am J Roentgenol 176:681-688,2001
 
P.338 掲載の参考文献
1) 三浦健,他:動注ポート造設法.外科 70:1465-1472,2008
 
2) 三浦健,他:癌の動注化学療法.写真で学ぶ日本の手術Vol.2, インターメデイカ, 東京, 657-678,2009
 
3) 三浦健,他:化学塞栓と動注化学療法を併用した肝細胞癌の治療成績. 埼玉医会誌 34:783-789,2000
 
P.340 掲載の参考文献
1) Lai ECH,et al:Spontaneous rupture of hepatocellular carcinoma;a systematic review.Arch Surg 141:191-198,2006
PubMed
2) Shuto T,et al:Delayed hepatic resection for ruptured hepatocellular carcinoma.Surgery 124:33-37,1998
PubMed
P.342 掲載の参考文献
1) Takayasu K,et al:Superselective transarterial chemoembolization for hepatocelluar carcinoma.Validation of treatment algorithm proposed by Japanese guidelines.J Hepatol 56:886-892,2012
 
2) 日本肝臓学会編:科学的根拠に基づく肝癌診療ガイドライン, 2009年版, 11, 金原出版, 東京, 2009
 
3) Bruix J,et al:Management of hepatocellular carcinoma:an update.Hepatology 53:1020-1022,2011
PubMed
4) Arii S,et al:Management of hepatocellular carcinoma:report of consensus meeting in the 45th annual meeting of the Japan Society of Hepatology.Hepatol Res 40:667-685,2010
PubMed
5) 日本肝臓学会編:肝癌診療マニュアル,第2版,医学書院,東京,120,2010
 
P.347 掲載の参考文献
1) Llovet JM,et al:Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma:resection versus transplantation.Hepatology 30:1434-1440,1999
PubMed
2) Bigourdan JM,et al:Small hepatocellular carcinoma in Child A cirrhotic patients:hepatic resection versus transplantation.Liver Transpl 9:513-520,2003
 
3) Belghiti J,et al:Resection prior to liver transplantation for hepatocellular carcinoma.Ann Surg 238:885-893,2003
PubMed
4) Hwang S,et al:Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma.Liver Transpl 13:761-766,2007
 
5) Cherqui D,et al:Liver resection for trans plantable hepatocellular carcinoma.Long-term survival and role of secondary liver trans plantation.Ann Surg 250:738-746,2009
 
P.349 掲載の参考文献
1) 日本肝移植研究会:肝移植症例登録報告.移植 46:524-541,2011
Medical*Online
2) http://www.mhlw.go.jp/topics/2006/03/dl/tp0314-1b35.pdf
 
3) 日本肝臓学会編:肝癌診療ガイドライン,第2版,金原出版,東京, 2009
 
4) Mazzaferro V,et al:Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med 334:693-699,1996
PubMed
5) Tamura S,et al:Living donor liver transplantation for hepatocellular carcinoma:the Japanese experience.Oncology 81(Suppl 1):111-115,2011
 
P.352 掲載の参考文献
1) 日本肝移植研究会:肝移植症例登録報告.移植 46:524-536,2011
Medical*Online
2) Takayama T,et al:Living-related transplantation of left liver plus caudate lobe.J Am Coll Surg 190:635-638,2000
 
3) Kokudo N,et al:Reconstruction of isolated caudate portal vein in left liver graft.Liver Transpl 10:1163-1165,2004
PubMed
4) Yamazaki S,et al:The technical advance and impact of caudate lobe venous reconstruction in left liver:additional safety for living-related donor liver transplantation.Transpl Int 23:345-349,2010
PubMed
5) Imamura H,et al:Pringle's manoeuvre in living donors.Lancet 360:2049-2050,2002
 
P.356 掲載の参考文献
1) Lo CM,et al:Extending the limit on the size of adult recipient in living donor liver transplantation using extended right lobe graft.Transplantation 63:1524-1528,1997
PubMed
2) Kokudo N,et al:Tailoring the type of donor hepatectomy for adult living donor liver transplantation.Am J Transplant 5:1694-1703,2005
PubMed
3) Sano K,et al:Evaluation of hepatic venous congestion:proposed indication criteria for hepatic vein reconstruction.Ann Surg 236:241-247,2002
PubMed
4) Lo CM:Complications and long-term outcome of living liver donors:a survey of 1,508 cases in five Asian centers.Transplantation 75(Suppl 3):S12-15,2003
 
5) Trotter JF,et al:Adult-to-adult transplantation of the right hepatic lobe from a living donor.N Engl J Med 346:1074-1082,2002
PubMed
P.359 掲載の参考文献
1) Togashi J,et al:Basiliximab as therapy for acute rejection after liver transplantation for hepatitis C virus cirrhosis.Biosci Trends 5:57-60,2011
PubMed
2) 羽賀博典,他:肝臓移植.日本移植学会,日本病理学会編:ヒト移植臓器拒絶反応の病理組織診断基準, 第2版, 金原出版, 東京, 44-56,2009
 
3) Banff schema for grading liver allograft rejection:an international consensus document.Hepatology 25:658-663,1997
PubMed
4) Banff Working Group:Liver biopsy interpretation for causes of late liver allograft dysfunction.Hepatology 44:489-501,2006
 
5) 金子順一:術後外来管理.國土典宏,他編:よくわかる肝移植, 第1版, 南江堂, 東京, 93-100,2011
 
P.362 掲載の参考文献
1) 日本肝移植研究会:肝移植症例登録報告.移植 45:621-632,2010
Medical*Online
2) Lerut JP,et al:Cavocaval liver transplantation without venovenobypass and without temporary portocaval shunting:the ideal technique for adult liver grafting? Transpl Int 10:171-179,1997
 
3) Fisher RA,et al:A2ALL Study Group.Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation.Am J Transplant 7:1601-1608,2007
 
4) Lo CM,et al:The role and limitation of living donor liver transplantation for hepatocellular carcinoma.Liver Transpl 10:440-447,2004
PubMed
P.364 掲載の参考文献
1) Fujiki M,et al:General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation:necessity or option? Liver Int 31:1081-1089,2011
PubMed
2) Graziadei et al:Chemoembolization followed by Liver Transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.Liver Transplant 9:557-563,2003
PubMed
3) Lu DS,et al:Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation.Hepatology 41:1130-1137,2005
PubMed
4) Cherqui D,et al:Liver resection for transplantable hepatocellular carcinoma:long-term survival and role of secondary liver transplantation.Ann Surg 250:738-746,2009
PubMed
5) Vitale A,et al:Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation:a cost-benefit analysis while awaiting data on sorafenib safety.Hepatology 51:165-173,2010
PubMed
P.366 掲載の参考文献
1) 日本肝臓学会編:科学的根拠に基づく肝癌診療ガイドライン, 2009年版, 金原出版, 東京, 2009
 
2) Ghobrial RM,et al:A 10-year experience of liver transplantation for hepatitis C:analysis of factors determining outcome in over 500 patients.Ann Surg 234:384-393,2001
PubMed
3) Lim HL,et al:Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection.Gastroenterology 106:248-251,1994
 
4) Sugawara Y,et al:Living donor liver transplantation for hepatitis B cirrhosis.Liver Transpl 9:1181-1184,2003
PubMed
5) Todo S,et al:Living donor liver transplantation for adult patients with hepatocellular carcinoma:experience in Japan.Ann Surg 240:451-459,2004
PubMed
P.370 掲載の参考文献
1) 日本肝移植研究会:肝移植症例登録報告.移植 46:524-536,2011
Medical*Online
2)「臓器の移植に関する法律」の運用に関する指針(ガイドライン)一部改正http://www.mhlw.go.jp/bunya/kenkou/zouki_ishoku/dl/hourei_07.pdf
 
3) 臓器の移植に関する法律http://www.jotnw.or.jp/jotnw/law_manual/pdf/organtransplant-law.pdf
 
4) 日本臓器移植ネットワークホームページhttp://www.jotnw.or.jp/
 
5) 肝臓移植希望者(レシピエント)選択基準http://www.jotnw.or.jp/jotnw/law_manual/pdf/rec-liver.pdf
 
P.374 掲載の参考文献
1) Ando E,et al:Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis:analysis of 48 cases.Cancer 95:588-595,2002
PubMed
2) Ueshima K,et al:Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma.Oncology 78(Suppl 1):148-153,2010
 
3) 浦山直樹,他:進行肝細胞癌に対する肝動注化学療法114例の検討.肝臓 52:449-460,2011
 
4) Takaki-Hamabe S,et al:Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma:Is the addition of subcutaneous interferon-alpha-2 b beneficial? Hepatol Res 39:223-230,2009
 
5) Yamasaki T,et al:Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.J Gastroenterol 40:70-78,2005
PubMed
P.376 掲載の参考文献
1) 日本肝臓学会編:科学的根拠に基づく肝癌診療ガイドライン, 2009年版, 金原出版, 東京, 12-13,2009
 
2) 日本肝臓学会編:肝癌診療マニュアル, 第2版, 医学書院,東京, 124-125,2010
 
3) Oken MM,et al:Toxicity and response criteria of the Eastern Cooperative Oncology Group.Am J Clin Oncol 5:649-655,1982
 
P.381 掲載の参考文献
1) 日本肝臓学会:肝癌診療マニュアル,第2版,医学書院,東京, 2010
 
2) Llovet JM,et al:Sorafenib in advanced hepatocellular carcinoma.N Engl J Med 359:378-390,2008
PubMed
3) Cheng AL,et al:Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma:A phase iii randomised,double-blind,placebo-controlled trial.Lancet Oncol 10:25-34,2009
 
4) Furuse J,et al:Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.Cancer Sci 99:159-165,2008
PubMed
5) Ueshima K,et al:Des-gamma-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma.Dig Dis. 29:321-325,2011
PubMed
P.384 掲載の参考文献
1) Onishi H,et al:Stereotactic body radiotherapy(SBRT)for operable stage I non-small-cell lung cancer:can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 81:1352-1358,2011
 
2) Takeda A,et al:Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies:Preliminary results for efficacy and toxicity.Hepatol Res 38:60-69,2008
 
3) Andolino DL,et al:Stereotactic body radiotherapy for primary hepatocellular carcinoma.Int J Radiat Oncol Biol Phys 81:447-453,2011
 
4) Price TR,et al:Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma.Cancer 10:1002,2011
 
5) Cardenes HR,et al:Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma.Clin Transl Oncol 12:218-225,2010
PubMed
P.387 掲載の参考文献
1) Zeng ZC,et al:A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma.Cancer J 10:307-316,2004
PubMed
2) Shim SJ,et al:Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma.Liver Int 25:1189-1196,2005
PubMed
3) Kawashima M,et al:Dose-volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinoma.Int J Radiat Oncol Biol Phys 79:1479-1486,2011
PubMed
4) Chiba T,et al:Proton beam therapy for hepatocellular carcinoma:a retrospective review of 162 patients.Clin Cancer Res 11:3799-3805,2005
PubMed
5) Mizumoto M,et al:Proton beam therapy for hepatocellular carcinoma:a comparison of three treatment protocols.Int J Radiat Oncol Biol Phys 81:1039-1045,2011
PubMed
P.391 掲載の参考文献
1) Kato H,et al:Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis.Int J Radiat Oncol Biol Phys 59:1468-1476,2004
PubMed
2) Kato H,et al:Phase II study of short-course carbon ion radiotherapy(52.8 GyE/4-fraction/1-week)for hepatocellular carcinoma.Hepatology 42(Suppl 1):381A, 2005
 
3) Kato H,et al:Two-fraction carbon ion radiotherapy for hepatocellular carcinoma:Preliminary results of a phase I/II clinical trial.J Clin Oncol 23(Suppl):338s, 2005
 
4) Imada H,et al:Comparison of efficacy and toxicity of short-course carbon ion radiotherapy for hepatocellular carcinoma depending on their proximity to the porta hepatis.Radiotherapy and Oncology 96:231-235,2010
 
5) Imada H,et al:Compensatory enlargement of the liver after treatment of hepatocellular carcinoma with carbon ion radiotherapy-relation to prognosis and liver function.Radiotherapy and Oncology 96:236-242,2010
PubMed
P.400 掲載の参考文献
1) 日本肝癌研究会編:原発性肝癌取扱い規約, 第5版, 金原出版, 東京, 2008
 
2) 日本肝臓学会編:肝癌診療マニュアル, 医学書院, 東京, 2007
 
3) Theise ND,et al:Hepatocellular carcinoma.WHO Classification of Tumors of the Digestive System,4th ed,IARC,Lyon,2010
 
4) International Consensus Group for Hepatocellular Neoplasia:Pathologic diagnosis of early hepatocellular carcinoma:A report of the international consensus group for hepatocellular neoplasia.Hepatology 49:658-664,2009
 
P.403 掲載の参考文献
1) Aoyagi Y,et al:Clinical significance of simultaneous determination of alpha-fetoprotein and des-gamma-carbxy prothrombin in monitoring recurrence of patients with hepatocellular carcinoma.Cancer 77:1781-1786,1996
PubMed
2) Aoyagi Y,et al:Fucosylation index of alpha-fetoprotein as a possible prognostic indicator in patients with hepatocellular carcinoma.Cancer 83:2076-2082,1998
PubMed
3) 佐藤繁樹,他:新規マイクロチップ電気泳動イムノアッセイシステムによるAFP-L3%測定試薬の評価.臨床病理 158:1155-1161,2010
 
4) Kobayashi M,et al:Highly sensitive AFP-L3% is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre-and postoperatively.Hepatol Res 41:1036-1045,2011
PubMed
P.406 掲載の参考文献
1) Wu P,et al:Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers.Am J Pathol 149:1167-1175,1996
PubMed
2) Komuta M,et al:Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin.Hepatology 47:1544-1556,2008
 
3) Tsuchiya K,et al:Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation.Oncology 80:278-288,2011
PubMed
4) Hoshida Y,et al:Gene expression in fixed tissues and outcome in hepatocellular carcinoma.N Engl J Med 359:1995-2004,2008
PubMed
5) Boyault S,et al:Transcriptome classification of HCC is related to gene alterations and to new therapeutic target.Hepatology 45:42-52,2007
PubMed
P.408 掲載の参考文献
1) Liaw YF,et al:Cirrhosis Asian Lamivudine Multicentre Study Group.Lamivudine for patients with chronic hepatitis B and advanced liver disease.N Engl J Med 351:1521-1531,2004
PubMed
2) Wu JC,et al:Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma.J Hepatol 51:890-897,2009
PubMed
3) Singal AK,et al:Meta-analysis:interferon improves outcomes following ablation or resection of hepatocellular carcinoma.Aliment Pharmacol Ther 32:851-858,2010
PubMed
4) Lok AS,et al:Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.Gastroenterology 140:840-849,2011
PubMed
5) Kajiwara E,et al:Effectiveness of biweekly low-dosage peginterferon treatment on the improvement of serum alanine aminotransferase and a-fetoprotein levels.Hepatol Res 42:254-263,2012
 
P.410 掲載の参考文献
1) Kawaguchi T,et al:Branched-chain amino acids as pharmacological nutrients in chronic liver disease.Hepatology 54:1063-1070,2011
PubMed
2) Inoue M,et al:Influence of coffee drinking on subsequent risk of hepatocellular carcinoma:a prospective study in Japan.J Nat Cancer Inst 97:293-300,2005
PubMed
3) Muto Y,et al:Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis.Hepatol Res 35:204-214,2006
PubMed
4) Kawaguchi T,et al:Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection.Liver Int 30:479-486,2010
 
5) Kawaguchi T,et al:Hybrid training of voluntary and electrical muscle contractions reduces steatosis,insulin resistance,and IL-6 levels in patients with NAFLD:a pilot study.J Gastroenterol 46:746-757,2011
PubMed
P.413 掲載の参考文献
1) Kawaguchi T,et al:Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3.Am J Pathol 165:1499-1508,2004
PubMed
2) Kawaguchi T,et al:Branched-chain amino acids as pharmacological nutrients in chronic liver disease.Hepatology 54:1063-1070,2011
PubMed
3) Sumie S,et al:Significance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection.Oncol Rep 18:545-552,2007
PubMed
4) Taura N,et al:The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area.Med Sci Monit 17:PH7-11,2011
PubMed
5) Eslam M,et al:Use of HOMA-IR in hepatitis C.J Viral Hepat 18:675-684,2011
PubMed
P.415 掲載の参考文献
1) Ascha MS,et al:The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.Hepatology 51:1972-1978,2010
PubMed
2) Marrero JA,et al:NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States.Hepatology 36:1349-1354,2002
PubMed
3) Yamato I,et al:Postoperative outcomes of patients with hepatocellular carcinoma negative for all virus-related markers.Surg Today, 2013
PubMed
4) Hashimoto E,et al:Hepatocellular carcinoma in non-alcoholic steatohepatitis:Growing evidence of an epidemic? Hepatol Res 42:1-14,2012
PubMed
5) Takuma Y,et al:Nonalcoholic steatohepatitis-associated hepatocellular carcinoma:our case series and literature review.World J Gastroenterol 16:1436-1441,2010
PubMed

書評

最近チェックした商品履歴

Loading...